Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats

Anette M. Kunig, Vivek Balasubramaniam, Neil E. Markham, Danielle Morgan, Greg Montgomery, Theresa R. Grover, and Steven H. Abman

Pediatric Heart Lung Center, Department of Pediatrics, University of Colorado Health Sciences Center, The Children’s Hospital, Denver, Colorado

Submitted 7 September 2004 ; accepted in final form 12 May 2005


    ABSTRACT
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
VEGF signaling inhibition decreases alveolar and vessel growth in the developing lung, suggesting that impaired VEGF signaling may contribute to decreased lung growth in bronchopulmonary dysplasia (BPD). Whether VEGF treatment improves lung structure in experimental models of BPD is unknown. The objective was to determine whether VEGF treatment enhances alveolarization in infant rats after hyperoxia. Two-day-old Sprague-Dawley rats were placed into hyperoxia or room air (RA) for 12 days. At 14 days, rats received daily treatment with rhVEGF-165 or saline. On day 22, rats were killed. Tissue was collected. Morphometrics was assessed by radial alveolar counts (RAC), mean linear intercepts (MLI), and skeletonization. Compared with RA controls, hyperoxia decreased RAC (6.1 ± 0.4 vs. 11.3 ± 0.4, P < 0.0001), increased MLI (59.2 ± 1.8 vs. 44.0 ± 0.8, P < 0.0001), decreased nodal point density (447 ± 14 vs. 503 ± 12, P < 0.0004), and decreased vessel density (11.7 ± 0.3 vs. 18.9 ± 0.3, P < 0.001), which persisted despite RA recovery. Compared with hyperoxic controls, rhVEGF treatment after hyperoxia increased RAC (11.8 ± 0.5, P < 0.0001), decreased MLI (42.2 ± 1.2, P < 0.0001), increased nodal point density (502 ± 7, P < 0.0005), and increased vessel density (23.2 ± 0.4, P < 0.001). Exposure of neonatal rats to hyperoxia impairs alveolarization and vessel density, which persists despite RA recovery. rhVEGF treatment during recovery enhanced vessel growth and alveolarization. We speculate that lung structure abnormalities after hyperoxia may be partly due to impaired VEGF signaling.

bronchopulmonary dysplasia; lung development; vascular endothelial growth factor; angiogenesis


BRONCHOPULMONARY DYSPLASIA (BPD) is the chronic lung disease of infancy that follows ventilator and oxygen therapy for respiratory distress syndrome after premature birth (37). Although the mechanisms that cause BPD are not completely understood, surfactant deficiency, ventilator-induced lung injury, oxygen toxicity, and inflammation are important pathogenic factors (21). Traditionally, BPD has been characterized by severe chronic lung injury with striking fibrosis and cellular proliferation. With advancements in perinatal care including exogenous surfactant administration, improved ventilator management, and antenatal steroids, the clinical course and lung histology of BPD have changed. Infants with BPD now have less severe acute respiratory disease, and at autopsy, lung histology is characterized by arrested lung development including alveolar simplification and dysmorphic vascular growth (1, 18, 21, 37).

Mechanisms that impair lung growth and cause persistent abnormalities in lung structure in premature infants with BPD remain poorly understood. Recently, experimental studies have shown that growth of the pulmonary circulation and alveolarization are closely coordinated, as demonstrated by findings that disruption of angiogenesis impairs lung structure (20). Treatment of neonatal rats with antiangiogenic agents, including fumagillin and thalidomide, decreases alveolarization and lung growth in infant rats, which is similar to the lung histology of BPD (20). Treatment of newborn rats with the vascular endothelial growth factor (VEGF) receptor inhibitor, SU-5416, also decreases alveolarization and vascular growth, suggesting that impaired VEGF signaling may contribute to abnormal lung structure after neonatal lung injury (20, 25). Interestingly, lung VEGF expression is decreased after hyperoxia in rabbits and in a primate model of BPD (30, 32). Clinical studies further support the hypothesis that decreased VEGF expression contributes to the pathogenesis of BPD (4, 24).

Previous animal studies have shown that exposure to hyperoxia in the neonatal period causes lung structural changes that are similar to the histology seen in human infants with BPD (39, 45, 46). Lung histology after hyperoxia is characterized by reduced complexity of the distal lung with decreased alveolar number and vascular growth (39, 40, 45, 46). Mechanisms by which hyperoxia inhibits lung growth in BPD and potential therapeutic strategies to improve lung growth in BPD remain unknown. Neonatal hyperoxia reduces lung VEGF mRNA and protein expression, suggesting that downregulation of VEGF may contribute to the simplified lung structure seen in this model (23, 30, 31). Recent studies further suggest that the reduction in VEGF protein persists beyond the hyperoxic injury and into the recovery period (27). However, whether late treatment with VEGF after hyperoxia can improve lung growth during recovery is unknown.

Therefore, we hypothesized that treatment with recombinant human VEGF (rhVEGF) protein would enhance alveolarization and vascular growth in infant rats during recovery from neonatal hyperoxia. To address this question, we studied the effects of rhVEGF treatment on lung structure during recovery from hyperoxia. We report that rhVEGF treatment improves alveolarization and vessel growth in infant rats during recovery after neonatal hyperoxia.


    METHODS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Animals

All procedures and protocols were approved by the Animal Care and Use Committee at the University of Colorado Health Sciences Center. Pregnant Sprague-Dawley rats were purchased (Harlan Laboratories, Indianapolis, IN) and maintained at Denver’s altitude (1,600 m; barometric pressure, 630 mmHg; inspired oxygen pressure, 122 mmHg) for at least 1 wk before giving birth. Pups were delivered naturally at term gestation. Litter size was standardized to 10 pups. Animals were fed ad libitum and exposed to day-night cycles alternatively every 12 h throughout the study period.

Study Design

Four groups of animals were used in these experiments with 10 animals in each group (Fig. 1). All pups were maintained in room air for the first 24–36 h of life to allow successful transition to postnatal life before randomization to study groups. On postnatal day 3, half of the animals were placed in 75% oxygen, and half remained in room air for the next 12 days. On postnatal day 14, all animals were placed in room air. The animals were randomly assigned to treatment with rhVEGF or saline. Half the animals in each litter were treated with intramuscular injections of rhVEGF at a dose of 20 mg/kg, and half were treated with normal saline injections for a total of 7 days. The four study groups included hyperoxia + VEGF (H+V), hyperoxia + normal saline (H+NS), room air + VEGF (RA+V), and room air + normal saline (RA+NS). Litters of randomly divided rat pups and their dams were placed in Plexiglas chambers containing 75% oxygen or room air. Oxygen concentrations were continuously monitored, and gas lines were filtered with charcoal and barium hydroxide to maintain CO2 levels <0.05%. Chambers were opened briefly (<10–15 min) for cleaning and injections. Animals were killed on postnatal day 22 with intraperitoneal injections of pentobarbital (3 mg/kg body wt), and lung tissue was harvested for analysis.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1. Study design. On postnatal day 2, rat pups were exposed to hyperoxia or room air (RA) for 12 days. On postnatal day 14 all animals were placed in RA. Rats were then randomized to daily injections of recombinant human (rh) VEGF or normal saline (NS) for 7 days and killed on postnatal day 22 for study.

 
Study Measurements

Body weight, lung weight, lung volume, right ventricular hypertrophy. Each animal was weighed before death. At autopsy, half the animals had lungs harvested for frozen tissue. Before freezing, wet lung weights were determined. The lungs of the remaining animals were fixed with paraformaldehyde, and subsequently lung volume was determined by displacement of water. Additionally, the heart was resected through a midline sternotomy. The right ventricle (RV) was dissected from the left ventricle and septum (LV+S). The RV and LV+S were weighed separately and the ratios of RV to LV + S weights were determined as a standard assessment of right ventricular hypertrophy (RVH) (12).

Fixation of lung tissue. Rat lungs were prepared and fixed in situ at the time of death on day 22. A midline sternotomy was made. Lungs and heart were exposed. The left atrium was incised to allow drainage of perfusate. Phosphate-buffered saline (PBS) was then injected into the right ventricle to flush the pulmonary circulation free of blood. The trachea was cannulated, and 4% paraformaldehyde was instilled into the lungs under constant pressure (30 cmH2O) for 30–60 min. This inflation pressure was chosen based on a previous study evaluating optimal inflation pressure (3, 15). The trachea was then ligated with the lungs under continued distending pressure. Lungs were removed and submersed in fixative for 24 h at room temperature.

Lung morphometric analysis. Transverse sections were obtained from the midplane of the upper, middle, and lower lobes of the formalin-fixed right lung for morphometric analysis. Sections from each animal were processed and embedded in paraffin wax. Paraffin sections (5 µm thick) were cut from each block and stained with hematoxylin and eosin. Analysis of each section was carried out in a blinded fashion. Alveolarization was assessed by performing radial alveolar counts (RAC), according to the method of Emery and Mithal (9, 10). From the center of the respiratory bronchiole, a perpendicular was drawn to the edge of the acinus (as defined by a connective tissue septum or the pleura), and the number of septa intersected by this line was counted. Six counts were performed for each animal.

For assessment of the mean linear intercept (MLI), six lung sections were selected in an unbiased fashion. Images of each section were captured with a Magnafire digital camera through an Olympus IX 81 microscope and were saved as PICT files. The images were then analyzed with the use of Stereology Toolbox software (Morphometrix, Davis, CA). The mean interalveolar distance was measured as the MLI, by dividing the total length of lines drawn across the lung section by the number of intercepts encountered, as described by Thurlbeck (10).

For assessment of skeletonization, six lung sections were selected in unbiased fashion. Images of each section were captured with a Magnafire digital camera through an Olympus IX 81 microscope and were saved as PICT files. Using digital image processing, SoveaPro (Reindeer Graphics), we transformed the lung parenchyma into a skeleton of curved and straight line segments with nodal and end points as described by Tschanz and Burri (43). The number of nodal points per high power field (hpf) was counted.

Immunohistochemistry and vessel volume density. Immunohistochemistry for factor VIII was performed to identify vessels for morphometric assessment. Paraffin-embedded slides from paraformaldehyde-fixed tissue were deparaffinized in CitriSolv (Fisher Scientific, Pittsburgh, PA). The sections were rehydrated by serial immersions in 100% ethanol, 95% ethanol, 70% ethanol, and water. Sections were digested with Proteinase K at a concentration of 500 µg/ml for 10 min at room temperature and then washed with PBS with 2.7 mM KCl, 1.2 mM KH2PO4, 138 mM NaCl, and 8.1 mM Na2HPO4. Endogenous peroxidase activity was reduced by immersion in 3% hydrogen peroxide in methanol. After rinsing, sections were covered in 10% goat serum for 30 min, and incubated with rabbit antifactor VIII antibody (1:1,000) diluted in PBS with 1% BSA and 0.1% sodium azide for 60 min. After incubation, the sections were rinsed with PBS and incubated with biotin-labeled secondary antibody (diluted 1:200 in PBS with 2% goat serum) for 30 min. After incubation with the secondary antibody, the sections were rinsed with PBS, incubated in ABC complex (Vector) for 30 min at room temperature, rinsed in PBS and developed with diaminobenzidine and hydrogen peroxide. Slides were lightly counterstained with hematoxylin. We then dehydrated the slides by sequential immersion in 70% ethanol, 95% ethanol, 100% ethanol, and CitriSolv before applying coverslips. Four lung sections were selected and captured by digital camera for analysis. The cells positive for factor VIII were stained brown. The number of factor VIII-positive vessels per high power field was counted. The magnification used was x20. Vessels immediately adjacent to large airways were excluded.

Statistical Analysis

Statistical comparison was made using analysis of variance and Fisher’s protected least-significant-difference test with Statview software package (Abacus Concepts, Berkeley, CA). Differences were considered significant at P < 0.05. The results were presented as means ± SE.


    RESULTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Body and lung weights and RVH

Ten animals were in each study group. Body weights of the hyperoxia group were higher than body weights of the RA group at the beginning and at the end of the experiment, reflecting differences between birth weights of the pups from the different litters. However, VEGF treatment did not alter body weight within either the hyperoxia or RA groups. Lung weights were also higher in the hyperoxia group than in the RA group, but there was no difference in lung weights after VEGF or saline treatment within the hyperoxia or RA groups. The lung-body weight ratios were not different between VEGF saline treatments in either the hyperoxia- or RA-exposed groups. (Table 1).


View this table:
[in this window]
[in a new window]
 
Table 1. Lung, heart, and body weights in study animals

 
Lung histology and morphometrics

In comparison with control animals (RA+NS), lung histology of animals exposed to hyperoxia (H+NS) was characterized by decreased septation, distal air space enlargement, and a reduction in complexity (Fig. 2). rhVEGF treatment during recovery after hyperoxia (H+VEGF) restored normal lung structure, which appears similar to the lung histology of RA-raised controls. rhVEGF treatment of animals raised in RA (RA+VEGF) had no apparent effect on distal lung structure. Additionally, there was no histological evidence of inflammation or edema in the VEGF-treated animals.



View larger version (136K):
[in this window]
[in a new window]
 
Fig. 2. Effects of rhVEGF treatment on lung histology after hyperoxia in infant rats. A: lung structure of neonatal rats in normoxia at 22 days. As shown, hyperoxia decreases lung septation and causes distal air space enlargement (B). rhVEGF treatment has no apparent affect on lung structure of rats maintained in normoxia (C), and rhVEGF treatment during recovery from hyperoxia increases alveolarization (D). Magnification is x20. Bar measures 100 µm.

 
To quantitate these differences, morphometric analysis was performed using three different techniques, including RAC, mean linear intercepts (MLI), and skeletonization. As shown, RAC were lower in rats after recovery from neonatal hyperoxia than in normoxia controls (6.1 ± 0.4 vs. 11.3 ± 0.4, P < 0.01; Fig. 3). rhVEGF treatment after hyperoxia increased RAC compared with hyperoxia controls (11.8 ± 0.5, P < 0.001, P = not significant vs. normoxia controls). Compared with RA controls, MLI was increased in neonatal rats after hyperoxia despite recovery in RA (44.0 ± 0.80 µm vs. 59.2 ± 1.8 µm, P < 0.001; Fig. 4). Infant rats that received daily rhVEGF injections during recovery from hyperoxia had lower MLI than hyperoxia-exposed controls (42.2 ± 1.2 µm, P < 0.001 vs. hyperoxia) and were not different from RA controls. MLI was increased in RA animals treated with rhVEGF compared with RA controls (52.8 ± 1.1 µm vs. 44.0 ± 0.8, P < 0.01). Compared with RA controls, nodal density as assessed by skeletonization was decreased after recovery from neonatal hyperoxia (503 ± 12 nodal points/hpf vs. 447 ± 14 nodal points/hpf, P < 0.01; Fig. 5). Treatment with rhVEGF in the hyperoxia-exposed group led to increased nodal density per hpf compared with hyperoxia alone and was the same as the normoxic controls (502 ± 7 nodal points/hpf, P < 0.01).



View larger version (11K):
[in this window]
[in a new window]
 
Fig. 3. Effects of rhVEGF treatment on radial alveolar counts (RAC) after hyperoxia in infant rats. As shown, hyperoxic exposure decreased RAC despite recovery in RA. rhVEGF treatment during recovery after hyperoxia increases RAC to similar values obtained from RA controls.

 


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4. Effects of rhVEGF treatment on mean linear intercepts (MLI) after hyperoxia in infant rats. Hyperoxia increased MLI, which persists despite RA recovery. As shown, rhVEGF treatment during recovery from hyperoxia decreased MLI to levels seen in RA controls.

 


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 5. Effects of rhVEGF treatment after hyperoxia on lung complexity as assessed by skeletonization. As shown, hyperoxia decreased the number of nodal points per high power field (hpf). rhVEGF treatment during recovery increased nodal point density to levels seen in RA controls.

 
Lung surface area, which was calculated from lung volume divided by MLI, was reduced in the hyperoxia animals compared with RA controls (0.040 ± 0.003 mm2 vs. 0.051 ± 0.002 mm2, P < 0.05; Fig. 6). Compared with hyperoxia controls, rhVEGF treatment increased surface area and was similar to values obtained from RA controls (0.056 ± 0.006 mm2, P < 0.01; Fig. 6). VEGF treatment of RA animals had decreased surface area compared with RA animals treated with saline (P < 0.05).



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6. Effects of rhVEGF treatment after hyperoxia on lung volume (top) and calculated surface area (bottom). As shown, there is no difference in lung volume between the 4 study groups. Surface area, which is calculated as lung volume divided by MLI, is reduced after hyperoxia exposure. With rhVEGF treatment during recovery from hyperoxia lung surface area is restored to levels seen in RA controls.

 
Vessel density was evaluated after factor VIII immunostaining of endothelial cells (Fig. 7). Compared with RA controls, hyperoxia reduced vessel density by 36% despite RA recovery (18.9 ± 0.3 vessels/hpf vs. 11.7 ± 0.3 vessels/hpf, P < 0.01; Fig. 8). Treatment with rhVEGF during recovery increased vessel density compared with hyperoxia alone (23.2 ± 0.4 vessels/hpf vs. 11.7 ± 0.3 vessels/hpf, P < 0.01). There was no difference in vessel density between RA controls and RA animals treated with rhVEGF. Vessel density in the hyperoxia-exposed group treated with rhVEGF was increased compared with the RA-exposed saline-treated animals and the RA-exposed rhVEGF-treated animals.



View larger version (112K):
[in this window]
[in a new window]
 
Fig. 7. Effects of rhVEGF treatment on vessel density after hyperoxia in infant rats. A: lung histology of neonatal rats in normoxia at 22 days stained with factor VIII. As shown, hyperoxia decreased lung growth (B). rhVEGF treatment had no effect on lung structure or vessel density of infant rats raised under normoxia (C). rhVEGF treatment during recovery from hyperoxia increased alveolarization, lung complexity, and vessel density (D). Magnification is x40. Bar measures 100 µm. Arrows indicate factor VIII-positive vessels.

 


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 8. Effects of rhVEGF treatment on vascular density after hyperoxia in infant rats. With hyperoxia exposure there was a decrease in the number of cells that stained positive for factor VIII. rhVEGF treatment during recovery after hyperoxia exposure resulted in an increase in the number of factor VIII- positive cells, which is similar to RA controls.

 

    DISCUSSION
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We found that exposure of infant rats to hyperoxia impairs distal lung growth as characterized by reduced complexity with increased terminal air space size and decreased alveolar number and vascular density and that these changes persist despite recovery in RA. We further show that treatment with rhVEGF protein during recovery from hyperoxia improves lung architecture as demonstrated by increased septation and lung complexity with increased surface area and vascular density. These findings further support the hypothesis that VEGF regulates angiogenesis and lung growth and that inhibition of alveolarization following neonatal hyperoxia may be partly due to sustained impairment of VEGF signaling, which persists during infancy despite recovery in RA. This report is the first to demonstrate that VEGF treatment following neonatal hyperoxia improves recovery of lung structure after hyperoxia. Our results suggest that VEGF treatment enhances alveolarization and vascular growth after hyperoxic lung injury in infant rats and that this may improve lung growth and prevent development of BPD in premature infants.

Animal models of hyperoxic lung injury have been used to study the mechanisms that contribute to the development of BPD (39, 45, 46). Although many pathogenic factors contribute to the development of BPD, impaired VEGF signaling may play a prominent role (20, 23, 30). Hyperoxia reduces lung VEGF expression in adult rats as well as neonatal rabbits (23, 30). A recent study has reported a sustained reduction in lung VEGF and VEGF receptor (VEGFR)-2 expression during prolonged hyperoxia and during the recovery period in infant rats (17). Treatment of neonatal rats with antiangiogenic agents, including SU-5416, a VEGF receptor inhibitor, decreases alveolarization and vascular growth (20), providing direct evidence that impaired VEGF signaling contributes to abnormal lung structure after neonatal lung injury. Clinical studies have shown that lung VEGF expression is decreased in human infants with fatal BPD (4), and VEGF protein levels are reduced in tracheal fluid of premature infants with BPD (24).

Mechanisms by which VEGF treatment improves lung growth during recovery from hyperoxia are uncertain but may be due to effects on endothelial cells, epithelial cells, or both. VEGF treatment may enhance endothelial cell growth, function, and survival, thereby increasing vascular growth that is necessary to sustain normal alveolarization (20). Endothelial cells are prone to oxidant injury, and the absence of VEGF, an important endothelial cell survival factor, may further increase susceptibility of the endothelium to hyperoxic stress. VEGF may have a direct effect on angiogenesis and alveolarization through liberation of nitric oxide (NO) (11, 14, 16, 20, 38). In addition, studies have shown a persistent reduction in VEGF protein following neonatal hyperoxic lung injury despite recovery in RA and that inhaled nitric oxide (iNO) preserves normal lung growth after disruption of VEGF signaling (27, 41). Several studies have also shown that lung endothelial nitric oxide synthase is also reduced in animal models of BPD (2, 28, 41). Previous studies have demonstrated that iNO during hyperoxia exposure may reduce acute lung injury in several animal models (13, 19, 34, 36, 44). These studies collectively suggest a critical role for the VEGF-NO signaling pathway during normal early postnatal lung development.

Alternatively, VEGF may have a direct effect on the pulmonary epithelium in promoting alveolarization. Studies have shown that VEGF may be involved in epithelial growth in fetal human lung explants in vitro and that exogenous VEGF can increase epithelial proliferation (5). A recent study has further demonstrated that VEGFR-2 transcripts are expressed by type II cells and that type II cells respond to VEGF treatment with increased surfactant protein (SP)-B and SP-C production (8).

In addition to the important role of VEGF signaling during normal lung development, recent studies have implicated VEGF in the pathophysiology of acute lung injury in various models (35). Genetic overexpression of VEGF causes pulmonary hemorrhage and edema in mice; however, these models are associated with dramatic increases in VEGF content (22, 26). Lung VEGF levels are reduced early in acute respiratory distress syndrome (ARDS) (29), and humans recovering from ARDS have increasing VEGF levels in epithelial lining fluid (42). These findings suggest that VEGF may have diverse roles including that of "permeability factor" by promoting early lung edema after injury, whereas VEGF may enhance recovery later in the course. Thus the roles of VEGF may depend on timing and degree of endothelial-epithelial cell injury, as well as the degree of altered VEGF expression. This study examined the effects of exogenous rhVEGF treatment only during the recovery phase after hyperoxia. Although we did not directly measure lung edema, we found no difference in lung weight, body weight, and lung-body weight ratio after VEGF treatment. Body weights and lung weights were higher in the hyperoxic group compared with the RA group at the beginning and end of the study due to differences in initial birth weights between the hyperoxia and RA litters at the onset of the experiment.

Interestingly, MLI was increased and surface area, which is calculated from MLI, was reduced in RA animals treated with VEGF compared with RA animals treated with NS. This may reflect the differences between morphometric methods. RACs and nodal points by skeletonization did not reflect this difference. Alternatively, VEGF treatment in RA animals may alter lung structure, as suggested in previous studies, which showed that huge increases in lung VEGF gene expression in newborn mice can cause lung injury (26).

There are several potential limitations of this study. First, the body weights of the hyperoxia group were higher than the RA group at the start of the study due to differences between litters. However, VEGF did not alter body weight in either hyperoxia or RA. Second, term animals rather than premature animals were used in this model of BPD. However, the alveolar phase of lung development in the newborn rat occurs during the first 3 wk of postnatal life (6, 7, 33), making this a useful time period during which to study mechanisms that impair lung growth. In addition, we studied the effects of VEGF treatment occurred during recovery after hyperoxia. Whether VEGF treatment during acute lung injury would have similar effects remains unknown. Mechanisms through which VEGF increases vessel and alveolar growth in this model are uncertain and are currently under investigation. Finally, rhVEGF protein administration may have adverse systemic effects but were not studied in this protocol.

In summary, we found that exposure of neonatal rats to hyperoxia results in impairment of alveolarization and vascular growth, which persists despite recovery in RA. We also report that rhVEGF treatment during the recovery period after neonatal hyperoxia restores normal lung architecture. Further studies are needed to determine the exact mechanisms by which VEGF treatment improves alveolarization and lung growth after neonatal hyperoxia, but these findings suggest that VEGF therapy may play a role in enhancing distal lung growth in BPD.


    FOOTNOTES
 

Address for reprint requests and other correspondence: A. Kunig, Pediatric Heart Lung Center, Section of Neonatology, Dept. of Pediatrics, Univ. of Colorado School of Medicine and The Children’s Hospital, PO Box 6508, F441, Aurora, CO (e-mail: anette.kunig{at}uchsc.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Abman SH. Bronchopulmonary dysplasia: "a vascular hypothesis". Am J Respir Crit Care Med 164: 1755–1756, 2001.[Free Full Text]
  2. Afshar S, Gibson LL, Yuhanna IS, Sherman TS, Kerecman JD, Grubb PH, Yoder BA, McCurnin DC, and Shaul PW. Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease. Am J Physiol Lung Cell Mol Physiol 284: L749–L758, 2003.[Abstract/Free Full Text]
  3. Bachofen H, Ammann A, Wangensteen D, and Weibel ER. Perfusion fixation of lungs for structure-function analysis: credits and limitations. J Appl Physiol 53: 528–533, 1982.[Abstract/Free Full Text]
  4. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, and Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 164: 1971–1980, 2001.[Abstract/Free Full Text]
  5. Brown KR, England KM, Goss KL, Snyder JM, and Acarregui MJ. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol 281: L1001–L1010, 2001.[Abstract/Free Full Text]
  6. Bucher JR and Roberts RJ. The development of the newborn rat lung in hyperoxia: a dose-response study of lung growth, maturation, and changes in antioxidant enzyme activities. Pediatr Res 15: 999–1008, 1981.[Abstract]
  7. Chen Y, Whitney PL, and Frank L. Comparative responses of premature versus full-term newborn rats to prolonged hyperoxia. Pediatr Res 35: 233–237, 1994.[Abstract]
  8. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, Nemery B, Dewerchin M, Van Veldhoven P, Plate K, Moons L, Collen D, and Carmeliet P. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8: 702–710, 2002.[ISI][Medline]
  9. Cooney TP and Thurlbeck WM. The radial alveolar count method of Emery and Mithal: a reappraisal 1–postnatal lung growth. Thorax 37: 572–579, 1982.[Abstract]
  10. Cooney TP and Thurlbeck WM. The radial alveolar count method of Emery and Mithal: a reappraisal 2–intrauterine and early postnatal lung growth. Thorax 37: 580–583, 1982.[Abstract]
  11. Ferrara N, Gerber HP, and LeCouter J. The biology of VEGF and its receptors. Nat Med 9: 669–676, 2003.[CrossRef][ISI][Medline]
  12. Fulton RM, Hutchinson EC, and Jones AM. Ventricular weight in cardiac hypertrophy. Br Heart J 14: 413–420, 1952.
  13. Gries DM, Tam EK, Blaisdell JM, Iwamoto LM, Fujiwara N, Uyehara CF, and Nakamura KT. Differential effects of inhaled nitric oxide and hyperoxia on pulmonary dysfunction in newborn guinea pigs. Am J Physiol Regul Integr Comp Physiol 279: R1525–R1530, 2000.[Abstract/Free Full Text]
  14. Grover TR, Parker TA, Zenge JP, Markham NE, Kinsella JP, and Abman SH. Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284: L508–L517, 2003.[Abstract/Free Full Text]
  15. Hayatdavoudi G, Crapo JD, Miller FJ, and O’Neil JJ. Factors determining degree of inflation in intratracheally fixed rat lungs. J Appl Physiol 48: 389–393, 1980.[Abstract/Free Full Text]
  16. Hood JD, Meininger CJ, Ziche M, and Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol Heart Circ Physiol 274: H1054–H1058, 1998.[Abstract/Free Full Text]
  17. Hosford GE and Olson DM. Effects of hyperoxia on VEGF, its receptors, and HIF-2alpha in the newborn rat lung. Am J Physiol Lung Cell Mol Physiol 285: L161–L168, 2003.[Abstract/Free Full Text]
  18. Husain AN, Siddiqui NH, and Stocker JT. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 29: 710–717, 1998.[CrossRef][ISI][Medline]
  19. Issa A, Lappalainen U, Kleinman M, Bry K, and Hallman M. Inhaled nitric oxide decreases hyperoxia-induced surfactant abnormality in preterm rabbits. Pediatr Res 45: 247–254, 1999.[Abstract]
  20. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, and Abman SH. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 279: L600–L607, 2000.[Abstract/Free Full Text]
  21. Jobe AH and Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163: 1723–1729, 2001.[Free Full Text]
  22. Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, and Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol 22: 657–664, 2000.[Abstract/Free Full Text]
  23. Klekamp JG, Jarzecka K, and Perkett EA. Exposure to hyperoxia decreases the expression of vascular endothelial growth factor and its receptors in adult rat lungs. Am J Pathol 154: 823–831, 1999.[Abstract/Free Full Text]
  24. Lassus P, Turanlahti M, Heikkila P, Andersson LC, Nupponen I, Sarnesto A, and Andersson S. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 164: 1981–1987, 2001.[Abstract/Free Full Text]
  25. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, and Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 283: L555–L562, 2002.[Abstract/Free Full Text]
  26. Le Cras TD, Spitzmiller RE, Albertine KH, Greenberg JM, Whitsett JA, and Akeson AL. VEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice. Am J Physiol Lung Cell Mol Physiol 287: L134–L142, 2004.[Abstract/Free Full Text]
  27. Lin YJ, Markham NE, Balasubmramaniam VB, Tang JR, Kinsella JP, and Abman SH. Inhaled nitric oxide therapy enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr Res. In press.
  28. MacRitchie AN, Albertine KH, Sun J, Lei PS, Jensen SC, Freestone AA, Clair PM, Dahl MJ, Godfrey EA, Carlton DP, and Bland RD. Reduced endothelial nitric oxide synthase in lungs of chronically ventilated preterm lambs. Am J Physiol Lung Cell Mol Physiol 281: L1011–L1020, 2001.[Abstract/Free Full Text]
  29. Maitre B, Boussat S, Jean D, Gouge M, Brochard L, Housset B, Adnot S, and Delclaux C. Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury. Eur Respir J 18: 100–106, 2001.[Abstract/Free Full Text]
  30. Maniscalco WM, Watkins RH, D’Angio CT, and Ryan RM. Hyperoxic injury decreases alveolar epithelial cell expression of vascular endothelial growth factor (VEGF) in neonatal rabbit lung. Am J Respir Cell Mol Biol 16: 557–567, 1997.[Abstract]
  31. Maniscalco WM, Watkins RH, Finkelstein JN, and Campbell MH. Vascular endothelial growth factor mRNA increases in alveolar epithelial cells during recovery from oxygen injury. Am J Respir Cell Mol Biol 13: 377–386, 1995.[Abstract]
  32. Maniscalco WM, Watkins RH, Pryhuber GS, Bhatt A, Shea C, and Huyck H. Angiogenic factors and alveolar vasculature: development and alterations by injury in very premature baboons. Am J Physiol Lung Cell Mol Physiol 282: L811–L823, 2002.[Abstract/Free Full Text]
  33. Massaro D, Teich N, Maxwell S, Massaro GD, and Whitney P. Postnatal development of alveoli. Regulation and evidence for a critical period in rats. J Clin Invest 76: 1297–1305, 1985.[ISI][Medline]
  34. McElroy MC, Wiener-Kronish JP, Miyazaki H, Sawa T, Modelska K, Dobbs LG, and Pittet JF. Nitric oxide attenuates lung endothelial injury caused by sublethal hyperoxia in rats. Am J Physiol Lung Cell Mol Physiol 272: L631–L638, 1997.[Abstract/Free Full Text]
  35. Mura M, dos Santos CC, Stewart D, and Liu M. Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol 97: 1605–1617, 2004.[Abstract/Free Full Text]
  36. Nelin LD, Welty SE, Morrisey JF, Gotuaco C, and Dawson CA. Nitric oxide increases the survival of rats with a high oxygen exposure. Pediatr Res 43: 727–732, 1998.[Abstract]
  37. Northway WH Jr, Rosan RC and Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 276: 357–368, 1967.[ISI][Medline]
  38. Papapetropoulos A, Garcia-Cardena G, Madri JA, and Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100: 3131–3139, 1997.[Abstract/Free Full Text]
  39. Roberts RJ, Weesner KM, and Bucher JR. Oxygen-induced alterations in lung vascular development in the newborn rat. Pediatr Res 17: 368–375, 1983.[Abstract]
  40. Shaffer SG, O’Neill D, Bradt SK, and Thibeault DW. Chronic vascular pulmonary dysplasia associated with neonatal hyperoxia exposure in the rat. Pediatr Res 21: 14–20, 1987.[Abstract]
  41. Tang JR, Markham NE, Lin YJ, McMurtry IF, Maxey A, Kinsella JP, and Abman SH. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 287: L344–L351, 2004.[Abstract/Free Full Text]
  42. Thickett DR, Armstrong L, and Millar AB. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med 166: 1332–1337, 2002.[Abstract/Free Full Text]
  43. Tschanz SA and Burri PH. A new approach to detect structural differences in lung parenchyma using digital image analysis. Exp Lung Res 28: 457–471, 2002.[CrossRef][ISI][Medline]
  44. Turanlahti M, Pesonen E, Lassus P, and Andersson S. Nitric oxide and hyperoxia in oxidative lung injury. Acta Paediatr 89: 966–970, 2000.[CrossRef][ISI][Medline]
  45. Warner BB, Stuart LA, Papes RA, and Wispe JR. Functional and pathological effects of prolonged hyperoxia in neonatal mice. Am J Physiol Lung Cell Mol Physiol 275: L110–L117, 1998.[Abstract/Free Full Text]
  46. Wilson WL, Mullen M, Olley PM, and Rabinovitch M. Hyperoxia-induced pulmonary vascular and lung abnormalities in young rats and potential for recovery. Pediatr Res 19: 1059–1067, 1985.[Abstract]